Everest Starts China Phase III Trial of ADC for Urothelial Cancer

Shanghai Everest Medicines has begun a China Phase III trial of sacituzumab govitecan-hziy in patients with metastatic urothelial cancer. The Everest trial is the China arm of a global test of the drug being conducted by Gilead . The candidate is a first-in-class, antibody-drug conjugate aimed at TROP-2, which is over-expressed in many epithelial cancers. In 2019, Everest entered an $835 million agreement ($65 million upfront) to acquire C hina r ights to the ADC. Everest completed a $451 million IPO in  Hong Kong  last year. More details.... Stock Symbols: (HK: 1952) (NSDQ: GILD) Share this with colleagues: // //